NASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free RZLT Stock Alerts $2.99 +0.14 (+4.91%) (As of 05/10/2024 08:55 PM ET) Add Compare Share Share Today's Range$2.85▼$3.0350-Day Range$1.78▼$3.5452-Week Range$0.72▼$3.69Volume121,100 shsAverage Volume300,435 shsMarket Capitalization$119.99 millionP/E RatioN/ADividend YieldN/APrice Target$8.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Rezolute alerts: Email Address Rezolute MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside194.3% Upside$8.80 Price TargetShort InterestHealthy0.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 5 Articles This WeekInsider TradingAcquiring Shares$306,601 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.12) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.26 out of 5 starsMedical Sector332nd out of 925 stocksPharmaceutical Preparations Industry145th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingRezolute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRezolute has only been the subject of 4 research reports in the past 90 days.Read more about Rezolute's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.78% of the outstanding shares of Rezolute have been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rezolute has recently increased by 29.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RZLT. Previous Next 1.9 News and Social Media Coverage News SentimentRezolute has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Rezolute this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for RZLT on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $306,601.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.80% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rezolute are expected to decrease in the coming year, from ($1.12) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Rezolute Stock (NASDAQ:RZLT)Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More RZLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RZLT Stock News HeadlinesMay 12, 2024 | nasdaq.comRezolute, Inc. Common Stock (NV) (RZLT) NewsMay 10, 2024 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) has caught the attention of institutional investors who hold a sizeable 47% stakeMay 13, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 23, 2024 | globenewswire.comPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingApril 19, 2024 | msn.comJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationApril 18, 2024 | markets.businessinsider.comOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment ProspectsApril 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 10, 2024 | benzinga.comRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, PredictionsMay 13, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 4, 2024 | insidermonkey.comInsiders Are Buying These 5 Penny StocksMarch 27, 2024 | finance.yahoo.comRezolute Reaches US$75m Market Cap Benefiting Insider Stock BuyingMarch 20, 2024 | investing.comRezolute's chief medical officer buys $18.8k in company stockMarch 6, 2024 | globenewswire.comRezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)February 22, 2024 | benzinga.comRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning CallsFebruary 16, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateFebruary 15, 2024 | finance.yahoo.comWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn RateFebruary 13, 2024 | finance.yahoo.comRezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateFebruary 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic EfficacyJanuary 24, 2024 | msn.comRezolute appoints Daron Evans as CFOJanuary 23, 2024 | msn.comRezolute secures innovation passport designation from U.K. for RZ358 treating hypoglycemiaJanuary 23, 2024 | finance.yahoo.comRezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital HyperinsulinismDecember 14, 2023 | finance.yahoo.comRezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital HyperinsulinismDecember 13, 2023 | finance.yahoo.comRezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)November 28, 2023 | msn.comRezolute (RZLT) Price Target Increased by 5.77% to 8.42November 24, 2023 | finanznachrichten.deRezolute, Inc.: Rezolute Reports First Quarter Fiscal 2024 ResultsNovember 18, 2023 | markets.businessinsider.comRezolute’s Promising Drug Pipeline and Market Position Validate Buy Rating: An Analysis of RZ358 and RZ402 PotentialNovember 17, 2023 | finance.yahoo.comRezolute to Participate in BTIG’s 3rd Annual Ophthalmology DaySee More Headlines Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/12/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RZLT CUSIPN/A CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$8.80 High Stock Price Target$14.00 Low Stock Price Target$5.00 Potential Upside/Downside+194.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.81% Return on Assets-48.05% Debt Debt-to-Equity RatioN/A Current Ratio12.00 Quick Ratio12.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book0.95Miscellaneous Outstanding Shares40,130,000Free Float31,781,000Market Cap$119.99 million OptionableNot Optionable Beta1.29 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Nevan Charles Elam J.D. (Age 57)Founder, CEO & Acting Chairman of the Board Comp: $973.65kDr. Brian Kenneth Roberts M.D. (Age 48)Chief Medical Officer Comp: $738.86kMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Financial Officer Dr. Davelyn Eaves Hood M.B.A.M.D., Director and Head of Scientific & Patient AffairsMr. Michael R. DeperroSenior VP & Head of Corporate DevelopmentMr. Michael CovarrubiasSenior VP & Head of Program & Portfolio ManagementMr. Chris MilksVP & Head of FinanceDr. Raj Agrawal M.D.VP & Head of Ophthalmological Clinical DevelopmentMs. Robyn SweinhartVP & Head of QualityMs. Erin O'BoyleSenior VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsRelmada TherapeuticsNASDAQ:RLMDSocietal CDMONASDAQ:SCTLOptiNoseNASDAQ:OPTNCellectar BiosciencesNASDAQ:CLRBPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 145,700 shares on 5/10/2024Ownership: 3.871%Acadian Asset Management LLCBought 90,346 shares on 5/10/2024Ownership: 0.225%Rosalind Advisors Inc.Bought 200,000 shares on 4/25/2024Ownership: 0.498%Vivo Capital LLCSold 445,138 shares on 4/22/2024Ownership: 6.972%Brian Kenneth RobertsBought 500 shares on 3/28/2024Total: $1,275.00 ($2.55/share)View All Insider TransactionsView All Institutional Transactions RZLT Stock Analysis - Frequently Asked Questions Should I buy or sell Rezolute stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RZLT shares. View RZLT analyst ratings or view top-rated stocks. What is Rezolute's stock price target for 2024? 5 Wall Street research analysts have issued 12-month price objectives for Rezolute's stock. Their RZLT share price targets range from $5.00 to $14.00. On average, they expect the company's stock price to reach $8.80 in the next year. This suggests a possible upside of 194.3% from the stock's current price. View analysts price targets for RZLT or view top-rated stocks among Wall Street analysts. How have RZLT shares performed in 2024? Rezolute's stock was trading at $0.9925 at the start of the year. Since then, RZLT shares have increased by 201.3% and is now trading at $2.99. View the best growth stocks for 2024 here. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) issued its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.27) earnings per share for the quarter, hitting the consensus estimate of ($0.27). What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), CymaBay Therapeutics (CBAY), Entasis Therapeutics (ETTX), Akero Therapeutics (AKRO), Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM) and Evelo Biosciences (EVLO). Who are Rezolute's major shareholders? Rezolute's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (6.97%), Vanguard Group Inc. (3.87%), Rosalind Advisors Inc. (0.50%) and Acadian Asset Management LLC (0.23%). Insiders that own company stock include Brian Kenneth Roberts, Daron Evans, Genexine Inc, Gil M Labrucherie, Nevan C Elam and Young-Jin Kim. View institutional ownership trends. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RZLT) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.